Clinical safety of 311c90: Aggregated data from patients and volunteers to date

European Neurology

Volumn 36, Issue , 1996, Pages 8-12

  Earl, Nancy L ^a  

^a GLAXOSMITHKLINE   (United States)

Author keywords

311C90; Adverse effects; Cardiovascular safety

Indexed keywords

SEROTONIN AGONIST; ZOLMITRIPTAN;

ARTICLE; ASTHENIA; BLOOD PRESSURE MEASUREMENT; DRUG SAFETY; DRUG TOLERABILITY; DYSPHAGIA; HUMAN; MIGRAINE; NAUSEA; ORAL DRUG ADMINISTRATION; OUTPATIENT; PARESTHESIA; PRIORITY JOURNAL; SOMNOLENCE; SYNCOPE; TACHYCARDIA; VERTIGO;

ADULT; AGED; BLOOD PRESSURE; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; HEART RATE; HUMANS; MIDDLE AGED; MIGRAINE DISORDERS; OXAZOLES; OXAZOLIDINONES; REFERENCE VALUES; SEROTONIN AGONISTS; TRYPTAMINES;

EID: 0030060964     PISSN: 00143022     EISSN: 14219913     Source Type: Journal    
DOI: 10.1159/000119097     Document Type: Article

References (9)

1. id receptor agonist in the acute oral treatment of migraine: a double blind, placebo controlled, dose range finding study. Neurology 1996:46:522-526.
2. Dahlóf C, Diener HC, Goadsby PJ, Massiou H, Olesen J, Schoencn J, Wilkinson M, Sweet RM, Klein KB: A multinational, double-blind, placebo-controlled, dose range finding study to investigate the efficacy and safety of oral doses of 311C90 in the acute treatment of migraine. Headache 1995:35:292.
3. Rapoport AM, Cady RK, Mathew NT, Ramadan NM, Taylor FR, Saper JR, Earl NL: Brown DL for the US 31IC90 Dose Ranging Study Group: Optimizing the oral dose of 31IC90 in the acute treatment of migraine. Cephalalgia 1995:15(suppl 14):221.
4. Goadsby PJ, Edvinsson L: Peripheral and central trigeminovascular activation in cat is blocked by serotonin (5-HT)-1D receptor agonist 31IC90. Headache 1994:34:394-399.
5. Mills A, Martin GR: Autoradiographic mapping of (H) sumatriptan binding in cat brain stem and spinal cord. Eur J Pharmacol 1995; 280:175-178.
6. Plosker GL, McTavish D: Sumatriptan: A reappraisal of its phamacology and therapeutic efficacy in the acute treatment of migraine and cluster headache. Drugs 1994:47:622-651
7. Lowy MT, Kench S, Miles P, for The International 311C90 Long-Term Study Group: Evaluation of the long-term safety and efficacy of 311C90 in the treatment of migraine. Cephalalgia 1995; 15(suppl 14):222.
8. Dixon R, On N, Seaber E, Rolan P, Posner J: Lack of an interaction between 3I1C90. a novel antimigraine compound, and oral ergota-minc in healthy subjects. Headache 1995: 35:304.
9. Smith DA, Phillips L, Fleck RJ, Lasseter KC, Shamblem S, Adam KD: 31IC90 in normotcn-sive and mild to moderate hypertensive volunteers: a pharmacodynamic and pharmacokinetic comparison. Cephalalgia 1995:15(suppl 14):219.